Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

Danish pharmaceutical group Novo Nordisk has cut sales and profit forecasts after replica drugs hit take-up of its blockbuster GLP-1 obesity and diabetes medicines Wegovy and Ozempic in the US.

Zepbound, the American firm’s weight-loss jab, was approved in its home country in November 2023, more than two years after Wegovy, made by Novo Nordisk, a Danish rival. Over the following year ...